Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357696 | 0.87 | PPARG (0.52) | PTGER4XDHSLC22A12GAATSHR | |
| SCHEMBL5364950 | 0.86 | EPAS1 (0.51) | EPAS1PTGER4GRM5PTGER2CYP3A4 | |
| SCHEMBL5363227 | 0.84 | EPAS1 (0.60) | EPAS1PTGER4PTGER2GAATSHR | |
| SCHEMBL4448975 | 0.81 | PTGER4 (0.62) | EPAS1PTGER4PTGER2GAATSHR | |
| SCHEMBL4447285 | 0.81 | PTGER4 (0.62) | EPAS1PTGER4PTGER2GAATSHR | |
| SCHEMBL5817933 | 0.81 | PTGER4 (0.42) | EPAS1PTGER4GRM5XDHSLC22A12 | |
| SCHEMBL5365760 | 0.79 | PTGER4 (0.77) | PTGER4PTGER2 | |
| SCHEMBL3981747 | 0.79 | NR4A2 (0.47) | PTGER4 | |
| SCHEMBL11577659 | 0.78 | GAA (0.54) | PTGER4PTGER2GAATSHRALDH1A1 | |
| SCHEMBL5357266 | 0.77 | GAA (0.51) | EPAS1PTGER4PTGER2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | EPAS1 1007/4885PTGER4 13/4885GRM5 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.